
Opinion|Videos|September 11, 2024
First-Line ICI-Based Combinations for mRCC With Sarcomatoid Features
Renal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.
Episodes in this series





































